Eric Lefkofsky is Fighting Cancer with Technology

By the year 2024, more than 18 million people will have cancer. This is 5million people who will be affected as compared to the year 2014. The good news is; things are going to change due to the introduction of Tempus. The main aim of Tempus is focusing on the way cancer is treated. The technology used is current, and every detail is captured for the advantage of most affected cancer patients.

Tempus does not only focus on data. It also goes a mile ahead to focus on the way information about all types of diseases is collected, analyzed and stored. There is a need to have progress notes which have points of interest of patients from the very beginning up to the end. Tempus uses software that can take in natural language and read characters written by a pen. All these advances and technologies are meant to make all-around structured information.

In most cases, human genome sequencing is very expensive. That is why Tempus is also fighting for cheap coats in conducting this process for patients. If that is achieved, the process of treating cancer will do starting from the cellular level. This will prevent much spread of cancer to other parts of the body.

All the above efforts are affected by Eric Lefkofsky and Tempus to accomplish the best outcomes. It is suspected that Eric Lefkofsky is doing this since his wife once had growth, and he felt bad about it. He is out to fight for people who do not have that power and capital to fight for themselves,thus making the society a better place.

Eric Lefkofsky is one of those people were born in 1969. He is a resident of Southfield, Michigan. He is one those who graduated from the University of Michigan with high-class honors. Eric owns the famous Juris Doctor Degree, and he is known to be very successful. Due to his excellent leadership skills, Eric Lefkofsky is known for holding top positions in many organizations in U.S.A. Some of the organizations are institutes like the Art Institute of Chicago and even children’s home.

For details:

Mikhail Blagosklonny: A Renowned Oncologist

Mikhail Blagosklonny is presently a scientist who is taking studies on cancer and aging. Before, Mikhail was specializing in oncology in the Roswell Institute, New York City. His academic qualifications are worth recognizing for he holds a degree in internal medicine and a doctorate in experimental medicine and cardiology. Mikhail started his career back in the New York Medical College as an associate professor in 2002. Later, he joined the Ordway Institute working as a senior scientist until 2009. He later became the professor of oncology at the Roswell Park Cancer Institute.

Due to his unending passion and dedication towards his career, Mikhail has been involved in a lot of research in the medical field. He engineered a research on cancer and its therapies when it comes to protecting normal body cells. He also led in the development of superior mechanisms and the making of anti-aging drugs. In cancer treatment, Mikhail has always advised people on the use of Rapamycin. Follow Mikhail on Google Scholar

Other than causing an impact on the field of medicine practically, Mikhail has also been actively involved in the editing of medicine-related research. Mikhail has championed writing on aging, cell cycle, and oncotarget. He has written books on the therapies of cancer and also in cells differentiation.

In one of the latest works on aging, he rules out the fact that aging is caused by the accumulation of molecular damage. He argues that aging is as a result of changes occurring in the deoxyribonucleic protein molecule. Mikhail boasts development of the hyper-function theory. He strongly believes that it is possible to control aging and cancer using the Rapamycin treatment. This treatment converts normal cells into senescent cells without any change of form of their molecular nature.

In one of his works on oncology, Mikhail states that due to the increased research on cancer and cancer-related therapies, there is an increase in the influx of knowledge. This will in turn force increased workforce that will help in the translation of the complex cancer knowledge to a normal clinical language. This will help in making it more understandable, and researchers will be able to deal with a large amount of data ensuring intensified research.

Mikhail’s other name in the research industry is Misha. Many researchers see him as a boost in the research sector. They believe that he is taking the search for new advanced strategies of cancer and aging to the next level. He has managed to publish at least 300 copies of research articles bearing his name. In the PLOS ONE, an American pathology industry, he is also involved in a lot of writing and research. Mikhail is seen as one who has a great love for humanity. In enthusiasm, he carries a great vision with him of seeing the world become a community with no trace of diseases.

Through hard work and great commitment in his passionate career, Mikhail Blagosklonny has been in the forefront to address issues of disease mitigation, and this has seen him make myriads of successful steps in his profession. Visit to know more about Mikhail

Eric Lefkofksy believes plummeting cost of gene sequencing may lead to cancer cure

As one indication of the breakneck speed of technological development, it’s instructive to look at the incredible reduction in costs of sequencing human genomes. In 2003, the year that the first complete individual human genome was sequenced, the cost to do so was over $100,000,000. Fast forward 14 years, and the cost of sequencing all of an individual’s genes is a relatively paltry $5,000. This is a quantum leap forward in the accessibility of gene sequencing.

But one man, Eric Lefkofsky, believes that not only will gene sequencing play a star role in future cancer research and treatment but that the cost of sequencing individual genomes will continue to plummet, possibly reaching less than $100 in the next decade. At these price levels, essentially every American’s genome could be easily and cheaply sequenced, leading to an explosion in potentially invaluable data that may lead cancer research to the point of finding a virtual cure.

While Lefkofsky is highly optimistic about the development of cheap gene sequencing and the likely impact that it will have on cancer research and treatment, he still urges caution about the expectations of exactly what such a wealth of new information will likely bring. Lefkofsky says that it is still not hugely likely that a universal cure will be found for all types of cancers. They are simply too heterogeneous, with some cancer types being notoriously resistant to treatment.

Instead, Lefkofsky envisions the coming decades bringing better and better treatments for certain subtypes of cancer. For example, cancers that already have solidly performing, well established treatment regimens, such as breast cancer or prostate cancer, may see additional advances that will all but constitute an actual cure. With others, Lefkofksy believes, treatments may advance to the point where having the disease is similar to those in advanced countries living with AIDS. These cancers will still be a serious disease, but with closely following their treatment regimen, those living with these cancers may be able to effectively survive indefinitely, dying from an unrelated cause.

Lefkofsky says that, while these outcomes would not technically amount to a cure, they are exciting enough to motivate an entire generation of research.

for more info: